Dutch government recommends children under 15 stay off TikTok and Instagram
The TikTok app logo is shown on an iPhone on Friday, Jan. 17, 2025, in Houston. (AP Photo/Ashley Landis, File)
THE HAGUE, Netherlands — The Dutch government advised parents on Tuesday not to have children under 15 use social media platforms such as TikTok and Instagram, citing psychological and physical problems among children using them, including panic attacks, depression and difficulties sleeping.
The Ministry of Health also encouraged parents to limit how long their children spend using electronic devices, keep phones and laptops out of bedrooms, and have 20 minutes of screentime followed by two hours of outside play.
The advisory 'gives children the time to further develop digital resilience and media literacy,' Vincent Karremans, caretaker deputy minister for youth and sport, said in a letter to parliament. Karremans is one of several ministers who remained on after the Dutch government collapsed earlier this month pending October elections.
Both TikTok and Instagram require users to be at least 13 years of age.
The guidelines, which are not legally binding, distinguish between 'social media' sites like TikTok and Instagram and 'social interaction platforms' such as messaging services WhatsApp and Signal. The social media sites have 'significantly more additive design features' that have a negative impact on children, the government said.
Children can use the messaging services from age 13, the year most Dutch children start secondary school, according to the recommendations.
Last year, Australia became the first country in the world to ban children under 16 from using social media. Denmark and France are considering similar legislation and Sweden issued recommendations about limiting screentime for kids last year.
A group of experts, put together at the request of the Dutch parliament, found that intense screentime and social media usage can result in physical and psychological problems in children.
Dutch schools have banned students from using tablets, cellphones and smart watches, with some exceptions, such as classes on media literacy.
In May, some 1,400 doctors and child welfare experts in the Netherlands signed a public letter, calling on the government to ban children under 14 from having cellphones and restricting social media usage until age 16.
In February, Dutch Queen Máxima said that her youngest daughter, Princess Ariane, had eyesight problems from spending too much time on mobile devices.
Molly Quell, The Associated Press
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Vancouver Sun
22 minutes ago
- Vancouver Sun
What is tech neck?
I'll be the first to admit I've never really had great posture. I've slouched for most of my life, and it's only gotten worse with the increasing use of smartphones and electronics. As it turns out, I'm not alone. Tech neck, a condition caused by prolonged use of technology, has been trending on TikTok and is becoming a growing issue and concern for many. To gain a better understanding of this growing phenomenon and to determine if I, too, have this condition, I connected with Dr. Fawad Malik, a chiropractor and the Clinic Director of UCC Physio, which has locations in Brampton and Vaughan. According to him, the term tech neck has become more widely recognized over the last decade as the dependence on electronic devices has grown. He shares that he has personally seen a noticeable increase in patients with tech neck symptoms, especially since the start of the COVID-19 pandemic, when many people transitioned to working and studying from home, often without proper ergonomic setups to support healthy posture. Following his expert guidance and advice, I've included a few product recommendations to help avoid tech neck. Discover the best of B.C.'s recipes, restaurants and wine. By signing up you consent to receive the above newsletter from Postmedia Network Inc. A welcome email is on its way. If you don't see it, please check your junk folder. The next issue of West Coast Table will soon be in your inbox. Please try again Interested in more newsletters? Browse here. This information is for educational purposes only. This information is not a substitute for professional care by a doctor or other qualified medical professional. Q: What is tech neck? A: Tech neck is a modern term used to describe persistent, ongoing pain and stiffness in the neck, upper shoulders and upper back. It is commonly caused by spending long periods looking down when using electronic devices such as smartphones, tablets and laptops. This constant forward-leaning posture places extra strain on the muscles and joints in the neck and upper back region. Q: How would one know if they have tech neck? What are the signs/symptoms? A: Typical symptoms of tech neck include pain, stiffness and tightness in the neck, upper shoulders and upper back, which can often lead to reduced neck mobility. In more severe cases, individuals may also experience headaches as well as numbness or a tingling sensation that radiates into the arms and hands. Other common signs include a forward head posture and discomfort in the neck, upper shoulders and upper back that is aggravated or worsened with prolonged use of electronic devices. These symptoms often improve with stretching, movement or taking regular breaks from screens. Q: What are some ways to prevent and or avoid tech neck? Any expert tips or tricks you can share? A: Preventing and/or avoiding tech neck begins with being mindful of your posture and making small, but consistent changes to your daily habits. When using electronic devices, it is very important to keep your screens at eye level to avoid constantly bending your neck forward and downwards, especially when using a computer. Smartphones should be held up at eye level when in use, rather than bending your neck forward and looking down. Looking down at your device for extended periods places significant strain on the neck and upper shoulders. It is also very important to take regular breaks when using screens, ideally every 45 to 60 minutes, to stretch and reset your posture. For individuals who rely on a computer screen throughout their work shift, i.e. office/admin roles, I usually recommend putting a timer on every 45 to 60 minutes and to step away from your desk for approximately five minutes to allow you to move, stretch and reset your posture, which helps reduce muscle tension and prevent the build-up of tension/stiffness that contributes to tech neck. Furthermore, incorporating simple exercises to strengthen your neck and upper back muscles, such as chin tucks, neck stretches and shoulder blade squeezes, can also help support proper posture. Using an ergonomic chair and adjusting your workstation can further reduce strain. When sitting, maintain good posture by keeping your head straight above your shoulders and your back and head resting against your chair. In my clinical experience, many people don't realize how often they hunch over until they start checking in with their posture throughout the day. Setting reminders on your phone or smartwatch can be a simple but great tool to build awareness and maintain proper posture habits. I have also noticed children are now much more reliant on electronic devices, whether it be for video games or tablets/laptops for school work, which is starting to impact their posture at a young age. Prolonged screen time and poor sitting habits, such as slouching or lying down while using electronic devices, can contribute to early signs of tech neck. Regular breaks should be encouraged, devices set up properly and physical activity promoted for a healthy posture and to prevent long-term issues as they grow. Q: Can tech neck be treated? If yes, how? A: If your symptoms of tech neck persist or worsen despite following the above recommendations, it is advisable to consult with your local chiropractor or physiotherapist. Treatment will typically involve manual therapy to relieve tension and stiffness in the affected area, along with personalized exercises to strengthen and improve your posture. These targeted interventions can significantly reduce the discomfort associated with tech neck. Additionally, committing to a daily postural exercise program as prescribed by your therapist will be key to managing symptoms and minimizing the risk of recurrence. Q: Do you have any product recommendations that may help? A: One of the most valuable investments you can make for yourself is investing in a proper ergonomic setup at your home or office workstation. Specifically, a good ergonomic chair that offers proper back and neck support, along with an adjustable ergonomic desk , can make a significant difference. If you rely on a laptop for daily work or study, I would highly recommend investing in a separate monitor. Monitors are typically positioned higher and closer to eye level, helping you avoid looking down at your laptop screen for extended periods, which can contribute to neck and upper back strain. You may also come across postural correcting straps/bands, typically known as posture correctors, available for purchase online. In my opinion, postural correctors may provide short-term benefits by providing support and reminding you to maintain your posture; however, their long-term use is not advised. To maintain long-term improvement, it is best achieved through a structured postural strengthening exercise program and consistent reminders to maintain proper posture during everyday activities. Providing 4D lumbar support that is fully adjustable, this ergonomic chair provides improved spinal alignment and lower back support. It is also made up of a breathable mesh and thick memory foam cushion that contours to the body for all-day maximum comfort. The chair has multiple recline angles and adjustable armrests, so you can truly get the perfect fit. Price: $300 Where to buy: Amazon A sturdy, flexible standing desk that is adjustable, making it easy to sit or stand with just one touch. With a built-in charger, custom height presets, child-lock and weight capacity of 440 pounds it makes it a versatile workstation. Read our full review here . Price: $529.99 Where to buy: Flexispot Made up of memory foam, this support pillow is designed to provide back pain relief, improve posture and maintain the natural curve of the spine. Price: $40 Where to buy: Amazon A 24-inch monitor that has height, tilt, swivel and pivot adjustability to ensure eye level positioning. Price: $250 Where to buy: Dell Although beneficial for short-term benefits, this posture corrector can help with the alignment of the back, neck and shoulder. It is adjustable and can be worn under clothes. Price: $28 Where to buy: Amazon Shopping Essentials , a category written by research-obsessed shopping fanatics, is now on . Explore in-depth product reviews, expert recommendations and exciting collaborations — plus get behind-the-scenes info on your favourite brands and trending products — learn more here or sign up for our newsletter
National Post
an hour ago
- National Post
Princess of Wales pulls out of engagement at Royal Ascot
The Princess of Wales canceled plans to attend Royal Ascot on Wednesday as she continues to balance the demands of her public duties against the realities of her recovery from cancer. Article content Kate, as Prince William's wife is commonly known, has been gradually returning to public duties since last fall, when she announced that she had completed chemotherapy and would return to work. At the time, she said her road to full recovery would be long and she would 'take each day as it comes.' Article content Article content Royal Ascot, a five-day series of horse races, is the centerpiece of the summer social season in Britain, with members of the royal family attending throughout the meeting. Racegoers had hoped to see Kate on Wednesday, as Prince William was scheduled to awarding race prizes. William attended without his wife. Article content Article content
Globe and Mail
2 hours ago
- Globe and Mail
GSK Stock Rises Almost 22% in 6 Months: Time to Buy, Sell or Hold?
GSK GSK stock has risen 21.5% in the past six months. The consistently strong performance of the Specialty Medicines unit, regulatory and pipeline successes and an optimistic outlook for the long term are the key factors driving the increase amid several headwinds like slowing sales in the Vaccines unit, generic competition for some drugs and broader economic pressure. Let's discuss these factors in detail to understand how to play GSK's stock amid the recent price increase. GSK Specialty Medicines Unit on a Strong Footing GSK is witnessing increased sales growth of its Specialty Medicines unit, particularly reflecting successful new launches in Oncology and long-acting HIV medicines. Sales are rising in all areas, HIV, Immunology/Respiratory as well as Oncology. Sales of the Specialty Medicines unit rose 19% in 2024, driven by double-digit growth in all therapy areas. The positive trend continues in 2025 with sales rising 17% in the first quarter of 2025. In the segment, while products like Nucala and Dovato are key top-line drivers, new long-acting HIV medicines, Cabenuva and Apretude, as well as new oncology drugs Jemperli and Ojjaara, are also witnessing strong patient demand and contributing to top-line growth. In 2025, the company expects sales in the Specialty Medicines segment to rise in a low double-digit percentage at CER, despite the impact from the Inflation Reduction Act or IRA. Specialty Medicines, which now accounts for around 40% of GSK's sales, is expected to be more than 50% of GSK's total revenue by 2031. GSK's Promising Pipeline GSK is increasing R&D investment in promising new long-acting and specialty medicines in Respiratory, Immunology & Inflammation, Oncology and HIV areas. GSK's pentavalent MenABCWY meningococcal vaccine and Blujepa/gepotidacin for treating uncomplicated urinary tract infection ('UTI') were approved in the United States in the first quarter of 2025. Its blockbuster drug Nucala was approved for treating chronic obstructive pulmonary disease or COPD, its fifth indication, in May 2025. Regulatory applications seeking approval of the Blenrep combination for relapsed/refractory multiple myeloma and depemokimab for two indications (chronic rhinosinusitis with nasal polyps or CRSwNP and asthma with type II inflammation) are under review in the United States and some other countries. FDA decisions on all these filings are expected in 2025. Blenrep combinations were approved in the United Kingdom and Japan in April/May 2025. In 2025, GSK expects to launch five new products/line extensions, including Blenrep, depemokimab (severe asthma and CRSwNP), Nucala for COPD, Penmenvy and Blujepa. Of these, Penmenvy, Blujepa and Nucala for COPD are already approved in the United States. GSK's Vaccine Sales Slowing Down GSK's first-quarter Vaccine sales declined 6% due to lower sales of its RSV vaccine, Arexvy, and shingles vaccine, Shingrix. U.S. sales of Shingrix declined 21% in the first quarter of 2025 due to lower demand as a result of challenges in activating harder-to-reach consumers. Arexvy's global sales declined 57% in the first quarter. Revised recommendations for RSV vaccinations issued in June 2024 by the U.S. Advisory Committee on Immunization Practices (ACIP) have been hurting sales of Arexvy from the second half of 2024 in the United States. In June, the ACIP recommended the use of Arexvy for all adults aged 75 and above. However, for adults aged 60-74, the ACIP recommended the vaccine only for those who are at increased risk of severe RSV disease. A challenging macro environment in China and potential for changes in vaccination policies in the United States are expected to hurt Vaccine sales in the near term. In 2025, the company expects sales in the Vaccines segment to decline by a low single-digit percentage at CER. GSK's Price Performance, Valuation & Estimate Movement GSK stock has risen 20.1% year to date compared with an increase of 4.0% for the industry. The stock has also outperformed the sector and the S&P 500 index, as seen in the chart below. The stock has also been trading above 200 and 50-day moving averages since May. GSK Stock Outperforms Industry, Sector and S&P GSK's stock is trading at an attractive valuation relative to the industry. Going by the price/earnings ratio, the company's shares currently trade at 8.63 on a forward 12-month basis, lower than 15.63 for the industry. The stock also trades below its 5-year mean of 10.25. The stock is much cheaper than several other large drugmakers like Eli Lilly LLY, Novo Nordisk NVO, AbbVie ABBV and AstraZeneca. GSK Stock Valuation Image Source: Zacks Investment Research The Zacks Consensus Estimate for earnings has risen from $4.26 to $4.42 per share for 2025 and from $4.71 to $4.82 per share for 2026 over the past 60 days. GSK's Estimates Stay Invested in GSK Stock GSK has its share of problems. Competitive pressure on HIV and respiratory drugs has risen. The dolutegravir HIV franchise patent expires in the 2028-2029 period, and U.S. vaccine sales are slowing down. In 2025, GSK also expects a negative sales impact of £400-500 million due to the impact of the IRA Medicare Part D redesign. However, the company is consistently growing its sales and profits, mainly driven by its Specialty Medicines segment. For the five-year period till 2026, GSK expects to record more than 7% sales growth while core operating profit is expected to increase more than 11% on a CAGR basis. In this period, Specialty Medicines is expected to rise in the low-to-mid teens percentage while General Medicines is expected to rise by a low single-digit percentage. The growth in Specialty Medicines and improvement in General Medicines are making up for a slowdown in the Vaccines unit. The company also resolved the vast majority of Zantac litigations in 2024, which had long been an overhang on the stock. GSK believes it is well-positioned to navigate and mitigate the potential financial impact of tariffs on pharmaceutical imports through supply chain and increased productivity initiatives We suggest investors who own this Zacks Rank #3 (Hold) stock stay invested for now, considering steady sales and profit improvement in the coming years. Consistently rising estimates also reflect analysts' optimistic outlook for future growth in profits. Buying the stock at its present cheap valuation can prove prudent for long-term investors who are interested in buying blue-chip companies. You can see the complete list of today's Zacks #1 Rank (Strong Buy) stocks here. 5 Stocks Set to Double Each was handpicked by a Zacks expert as the #1 favorite stock to gain +100% or more in the coming year. While not all picks can be winners, previous recommendations have soared +112%, +171%, +209% and +232%. Most of the stocks in this report are flying under Wall Street radar, which provides a great opportunity to get in on the ground floor. Today, See These 5 Potential Home Runs >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report GSK PLC Sponsored ADR (GSK): Free Stock Analysis Report Novo Nordisk A/S (NVO): Free Stock Analysis Report Eli Lilly and Company (LLY): Free Stock Analysis Report AbbVie Inc. (ABBV): Free Stock Analysis Report
